Clinical trial
A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab…
NCT01992653 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT01992653 |
|---|---|
| Title | A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma |
| Official title | A Phase Ib/II Study Evaluating the Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With B-Cell Non-Hodgkin's Lymphoma |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Non Hodgkin |
| Intervention type | Drug |
| Interventions | Cyclophosphamide, Doxorubicin, Obinutuzumab, Polatuzumab Vedotin, Prednisolone, Prednisone, Rituximab |
| Enrollment | 85 |
| Start date | Nov 29, 2013 |
| Primary completion | Dec 19, 2018 |
| Completion | Dec 19, 2018 |
| First posted | Nov 25, 2013 |
| Last update posted | Mar 14, 2023 |
| Countries | France, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: